Talkspace (TALK) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
18 Jan, 2026Executive summary
Q3 2024 revenue grew 23% year-over-year to $47.4 million, led by a 45% increase in Payor revenue and 17% growth in Direct-to-Enterprise revenue, while Consumer revenue declined 30%.
Net income was $1.9 million, compared to a $4.4 million loss a year ago, marking the third consecutive profitable quarter.
Adjusted EBITDA reached $2.4 million, up from a loss of $2.8 million in Q3 2023, with margin improvement and operational efficiency.
Covered lives expanded to nearly 160 million, up 40% year-over-year, with significant growth in Medicare, military, and teen-focused offerings.
Strategic partnerships, including Amazon Health Conditions, enhanced brand recognition and referral opportunities.
Financial highlights
Q3 2024 revenue was $47.4 million, up 23% year-over-year; nine-month revenue reached $138.9 million, up 29%.
Adjusted EBITDA for Q3 was $2.4 million, compared to a loss of $2.8 million in Q3 2023, with a margin of 5.0%.
Gross profit for Q3 was $21.6 million, with a gross margin of 45.6%, down from 48.8% a year ago.
GAAP net income was $1.9 million for Q3 2024.
Ended Q3 with $119 million in cash and cash equivalents, and no debt outstanding.
Outlook and guidance
Fiscal year 2024 revenue guidance is $185–$195 million, with adjusted EBITDA expected between $4 million and $8 million.
Management expects to fund cash needs for at least the next 12 months using existing cash balances.
Revenue growth in 2024 is driven by existing covered lives, with new Medicare and military segments expected to impact 2025.
Latest events from Talkspace
- Definitive agreement for acquisition by UHS to create a national behavioral health continuum.TALK
Proxy Filing9 Mar 2026 - Shareholders to receive $5.25 per share in all-cash merger, pending approvals and clearances.TALK
Proxy Filing9 Mar 2026 - UHS to acquire Talkspace for $835M, expanding virtual behavioral health services nationwide.TALK
Proxy Filing9 Mar 2026 - 2025 revenue up 22% to $229M, adjusted EBITDA up 127%, with strong 2026 growth outlook.TALK
Q4 202519 Feb 2026 - Director elections, auditor ratification, and executive pay were key agenda items.TALK
AGM 20243 Feb 2026 - Q2 revenue up 29%, net loss narrowed, and share repurchase authority expanded to $32M.TALK
Q2 20242 Feb 2026 - AI-driven solutions and payer partnerships drive growth and position the platform for leadership.TALK
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026 - Profitable, AI-driven behavioral health platform targets 200M covered lives and 25% annual growth.TALK
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Expanding in-network mental health access with AI innovation and targeted market growth.TALK
Barclays 27th Annual Global Healthcare Conference26 Dec 2025